Valuation: Syntara Limited

Market Cap 47.09M 33.01M 29.01M 27.33M 24.96M 46.68M 3.17B 327M 127M 1.61B 124M 121M 5.24B P/E 2027 *
-4.8x
P/E 2028 * -8x
Enterprise Value 14.29M 10.02M 8.8M 8.29M 7.57M 14.16M 961M 99.29M 38.57M 490M 37.61M 36.78M 1.59B EV / Sales 2027 *
-
EV / Sales 2028 * 4x
Free-Float
72.69%
Yield 2027 *
-
Yield 2028 * -
1 day+4.35%
1 week+4.35%
Current month-7.69%
1 month-7.69%
3 months+4.35%
6 months-20.00%
Current year-31.43%
1 week 0.02
Extreme 0.023
0.03
1 month 0.02
Extreme 0.023
0.03
Current year 0.02
Extreme 0.019
0.04
1 year 0.02
Extreme 0.019
0.04
3 years 0.01
Extreme 0.014
0.1
5 years 0.01
Extreme 0.014
0.14
10 years 0.01
Extreme 0.014
0.37
Manager TitleAgeSince
Chief Executive Officer 64 2013-03-11
Director of Finance/CFO - 2024-08-30
Chief Tech/Sci/R&D Officer - 2022-06-30
Director TitleAgeSince
Director/Board Member 64 2013-03-11
Chairman 68 2023-10-02
Director/Board Member - 2022-12-15
Date Insider Type Main position Quantity % Market Cap. Importance
3/13/25 Buy

Director

9,753,442 0.6008%
9/24/24 Buy

Director

53,571,429 4.1513%
8/12/21 Expiration

Chief Executive Officer

471,000 0.1040%
Change 5-day change 1-year change 3-year change Capi.($)
+4.35%+4.35%-4.00%-29.41% 31.78M
-3.30%+2.97%+54.99%+104.15% 74.18B
-0.12%-1.63%+33.14%+74.86% 59.55B
+2.71%-0.84%-16.39%+364.46% 25.84B
+0.81%+3.58%+1.01%-5.14% 24.73B
-1.05%+2.58%+24.27%-10.32% 20.87B
-1.70%-4.15%+147.82%+325.69% 15.32B
+2.15%+2.06%+45.57%+169.79% 14.06B
-0.43%-5.32%-14.46%+775.94% 13.12B
+0.04%-3.00%+15.76%+234.69% 11.85B
Average +0.35%-0.29%+28.77%+200.47% 25.96B
Weighted average by Cap. -0.71%-0.22%+34.92%+160.27%

Financials

2027 *2028 *
Net sales - 5.5M 3.86M 3.39M 3.19M 2.92M 5.45M 370M 38.23M 14.85M 189M 14.48M 14.16M 612M
Net income -31.85M -22.33M -19.62M -18.49M -16.88M -31.57M -2.14B -221M -85.99M -1.09B -83.84M -82.01M -3.55B -31.5M -22.08M -19.41M -18.28M -16.7M -31.23M -2.12B -219M -85.04M -1.08B -82.92M -81.11M -3.51B
Net Debt -32.8M -22.99M -20.21M -19.04M -17.38M -32.51M -2.21B -228M -88.55M -1.12B -86.34M -84.46M -3.65B -25.1M -17.6M -15.46M -14.57M -13.3M -24.88M -1.69B -174M -67.77M -861M -66.07M -64.63M -2.79B
Logo Syntara Limited
Syntara Limited is an Australia-based clinical-stage drug development company. The Company is targeting extracellular matrix dysfunction with its amine oxidase chemistry and other technologies to develop novel medicines for blood cancers and conditions linked to inflammation and fibrosis. The Company’s lead candidate SNT-5505 is for the bone marrow cancer myelofibrosis which causes a build-up of scar tissue that leads to loss of red and white blood cells and platelets. The Company is also advancing topical pan-LOX inhibitors in scar revision, keloid scarring and scar prevention post-surgery. Its product candidate, SNT-4728, is an inhibitor to treat sleep disorders and slow progression of neurodegenerative diseases like Parkinson’s by reducing neuroinflammation. The Company’s other drug candidates target fibrotic and inflammatory diseases such as kidney fibrosis, NASH, pulmonary fibrosis and cardiac fibrosis.
Employees
-
Date Price Change Volume
26-09-24 A$0.0240 +4.35% 54,563
26-09-23 A$0.0230 -4.17% 1,996,423
26-09-22 A$0.0240 0.00% 274,526
26-09-21 A$0.0240 +4.35% 6,145,038
26-09-18 A$0.0230 0.00% 239,258
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
0.0240AUD
Average target price
0.1050AUD
Spread / Average Target
+337.50%

Quarterly revenue - Rate of surprise